Welcome to our dedicated page for Vaso SEC filings (Ticker: VASO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vaso Corporation filings document formal disclosures for a diversified medical technology company with network services, professional sales services, and proprietary medical products. Recent Form 8-K reports cover material events such as subsidiary-related transactions, executive compensation arrangements, and amendments to the company’s bylaws.
Proxy and shareholder-meeting filings describe Vaso’s board elections, advisory executive-compensation votes, meeting procedures, common-stock voting matters, and governance provisions. The filing record also identifies the company’s OTCQX-listed common stock context, wholly owned subsidiary structure, and recurring disclosure topics tied to operating results, governance, material agreements, and corporate actions.
Vaso Corporation reported essentially flat results for the quarter ended March 31, 2026, with revenue of $19.4 million versus $19.5 million a year earlier and a net loss of $0.9 million, slightly improved from a $1.1 million loss. Gross margin ticked up to 60%.
Professional sales service revenue rose 6% to $9.2 million, equipment revenue grew 27% to $0.6 million, and IT revenue fell 7% to $9.6 million, partly reflecting the prior VasoHealthcare IT divestiture. Cash declined to $22.0 million from $35.1 million after a $12.6 million operating cash outflow driven mainly by higher receivables and lower accrued liabilities. Deferred commission revenue reached $39.5 million, and total remaining performance obligations were about $103 million, highlighting a sizable contracted backlog, while GEHC accounted for 48% of quarterly revenue.
Vaso Corporation approved a new incentive arrangement for Peter Castle, President of its wholly-owned subsidiary VasoTechnology Inc. The agreement ties a potential $175,000 incentive payment to Mr. Castle’s role in helping Vaso achieve specified corporate outcomes related to potential strategic initiatives within a defined time period.
If the objectives laid out in the agreement are not achieved in time, or if Mr. Castle does not remain in compliance with the agreement’s terms, he will not receive any portion of the incentive amount.
Jun Ma filed a Schedule 13D reporting beneficial ownership of 10,498,146 shares of VASO Corp common stock, representing 6.0% of the class. Most of these shares, 9,749,834, were granted by the company, while 777,312 were purchased with personal funds.
Ma, who serves as President and CEO of Vaso Corporation, states the shares were acquired for investment purposes and under an Employment Agreement that allows participation in the company’s equity compensation programs at the board’s discretion. He reports sole voting and dispositive power over all of these shares and no transactions in the past 60 days.
VASO Corp's common stock has a major holder, with Joshua Markowitz reporting beneficial ownership of 56,088,318 shares, or 31.9% of the outstanding stock, through a mix of direct holdings, family trusts, and majority-owned companies.
The shares include 7,569,595 in a Non-GST Exempt Trust, 4,639,430 in a GST Exempt Trust, 25,714,286 held by Kerns Manufacturing Company, 17,815,007 held by Living Data Technology Corp., and 350,000 held directly. Markowitz acquired 50,000 shares with personal funds and received 300,000 as board compensation. Co-trustee Stacey Markowitz reports 12,209,025 shares, or 6.9%, via the same trusts. The holdings are described as being for investment purposes, with no transactions in the last 60 days.
Vaso Corporation reports higher 2025 revenue and profit across its three healthcare and IT segments. Total revenue rose 2.7% to $89.1 million, while net income increased to $1.57 million, helped by a tax benefit and gain on the sale of its VasoHealthcare IT unit.
The professional sales service segment tied to GE HealthCare remained the main earnings driver, with commission revenue up 6.9% and deferred commission revenue growing as booked orders outpaced deliveries. The IT segment recorded a goodwill impairment, and equipment revenue was roughly flat. Cash and cash equivalents reached $35.1 million, and the company extended its key GEHC agreement through 2030, supporting future revenue visibility.
Vaso Corporation reported that its board amended and restated the company’s bylaws, effective February 11, 2026. The changes give the board more flexibility in scheduling annual stockholder meetings, define what business can occur at special meetings, and add detailed provisions for virtual stockholder meetings and how meetings are chaired and conducted.
The amendments align quorum and board-size language with Vaso’s Articles of Incorporation and remove stockholders’ ability to act without a meeting. They also add a Chief Operating Officer role, separate the duties of the President and Chief Executive Officer, clarify and expand indemnification and expense advancement for officers, allow discretionary indemnification of non-officers, and expressly permit uncertificated shares.
Vaso Corporation reported the results of its annual shareholder meeting held on December 17, 2025. Shareholders elected three Class II directors — Behnam Movaseghi, Jane Moen, and Leon Dembo — to new three‑year terms. As of the record date, 175,953,035 common shares were entitled to vote, and 120,208,576 shares were represented in person or by proxy.
Shareholders approved the non-binding advisory proposal on executive compensation, with 105,612,284 votes for, 12,759,718 against, and 1,836,574 abstentions. In a separate advisory vote on how often to hold future Say on Pay votes, 97,734,812 votes favored a three‑year frequency. Holders of approximately 56% of outstanding shares supported this three‑year schedule, which the Board adopted, so the next Say on Pay vote will occur at the 2028 annual meeting.
Vaso Corporation reported that on November 19, 2025 it entered into an agreement to sell its wholly owned subsidiary, VasoHealthcare IT Corp. The announcement was made the same day through a press release, which is included as an exhibit to this report. This move means Vaso plans to exit direct ownership of its healthcare IT subsidiary, though specific terms such as price, buyer, and closing conditions are not described in this excerpt.
Vaso Corporation reported stronger Q3 results. Revenue rose to $22.657 million (up 9% year over year), driven by higher commissions in professional sales services and steady IT performance. Gross profit increased to $13.896 million (61% margin). Operating income was $1.538 million versus a loss last year, and net income reached $1.711 million (from a prior loss), reflecting higher segment gross profit and the absence of prior-year transaction costs.
The IT segment delivered $11.218 million with 87% recurring revenue; professional sales services generated $10.820 million; equipment contributed $0.619 million. Adjusted EBITDA improved to $1.617 million from a loss. Cash and cash equivalents were $34.859 million, supported by $9.012 million operating cash flow year-to-date. Deferred revenue stood at $39.412 million (including $21.854 million long term), and remaining performance obligations totaled $109.8 million. GE Healthcare represented 48% of Q3 revenue; total working capital was $20.308 million.
Vaso Corporation will hold its 2025 annual meeting on December 17, 2025 at 10:00 A.M. EST at Lever House, 390 Park Avenue, New York. Stockholders will vote on: (1) electing three Class II directors for three-year terms, (2) a non-binding Say on Pay advisory vote, and (3) a non-binding Say When on Pay vote on the frequency of Say on Pay.
The Board recommends voting FOR all director nominees, FOR Say on Pay, and for a three-year Say on Pay frequency. The record date is October 31, 2025, with 175,953,035 shares outstanding and entitled to vote. Officers and directors hold 43.85% of voting power and intend to vote consistent with these recommendations.
Holders may vote by Internet (www.proxyvote.com), phone (1-800-690-6903), mail, or in person. A quorum requires one-third of shares entitled to vote. The Board has determined that four of seven directors are independent under NASDAQ standards.